Research.Patient.info
Metastatic Castration-sensitive Prostate Cancer research hub
2 indexed studies · 0 currently recruiting
- active not recruitingPHASE3
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
This study is looking at a new treatment for men with prostate cancer that has spread and is responding to hormone therapy. It combines a drug called niraparib with standard treatments (abiraterone acetate and prednisone) to see if it works better for those with specific genetic changes.
United States · Argentina · Australia - active not recruitingPHASE3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
This study is testing a new drug, Saruparib, for men with advanced prostate cancer that is still responding to hormone treatment. It aims to see if adding Saruparib to standard hormone therapy works better than standard therapy alone to slow down cancer growth.
United States · Australia · Austria